When the Trump administration slapped 100 percent tariffs on branded pharmaceuticals in April, India’s generic drugmakers breathed easy. The duties hit patented medicines, not the low-cost generics that are India’s stock-in-trade. For now, India’s pharma industry looks tariff-proof. But it is not China-proof, and that exposure is a problem not only for India but for the Western healthcare systems that depend on it.
India supplies close to 20 percent of the world’s generic medicines by volume. Indian firms account for roughly 47 percent of all generic prescriptions dispensed in the United States, and in five of the ten largest therapy areas, including hypertension, mental health, and lipid regulators, that share exceeds 50 percent. The UK’s National Health Service depends on India for roughly a third of its generic medicines.
Yet this formidable export machine runs on borrowed chemistry.
India sources around 70 percent of its bulk-drug imports from China, and the reliance has deepened over time. Chinese suppliers accounted for about 73 percent of India’s active pharmaceutical ingredient (API) imports in the first half of fiscal year 2026, up from 68 percent in FY2019. For everyday staples such as paracetamol, penicillin, and ibuprofen, China’s share exceeds 90 percent.
China produces roughly 40 percent of the world’s APIs. Its advantage is structural: economies of scale, cheaper industrial power, less stringent environmental enforcement, and decades of state-backed capacity building. India, despite its reputation as the pharmacy of the world, is a midstream player that depends on Chinese chemistry for the raw ingredients of almost every pill it exports.
This is not a problem that tariffs can solve. As the Diplomat’s Soumya Bhowmick put it in a recent analysis for the Observer Research Foundation, “a tariff wall can keep out a finished pill, but cannot keep out the chemistry inside it.”
The transitive risk
Were Beijing to restrict API or intermediate exports, whether as a deliberate geopolitical lever or a side effect of domestic energy shortages, environmental crackdowns, or pandemic shutdowns, the disruption would cascade. Indian factories would slow or stop. American pharmacy shelves would thin. British patients would face drug shortages.
This is not a hypothetical. In April 2026, Indian exporters warned of falling inventories of solvents and key starting materials. Raw material costs rose 20 to 30 percent before supplies stabilized. The episode was brief, but it illustrated the fragility of a system in which the world’s biggest supplier of finished generic drugs depends on a single country for the bulk of its raw inputs.
The US review of generic tariffs is due within a year of the April 2026 proclamation. The White House will need to decide whether to extend the 100 percent tariff to generics and biosimilars. But the real vulnerability is not at the finished-product stage. It is upstream, in the supply chains that American tariffs cannot reach.
What India is doing
New Delhi is not blind to the problem. Its Production-Linked Incentive (PLI) scheme for bulk drugs has helped restart domestic production of penicillin G after a gap of more than 20 years. The government claims it has commissioned capacity for 28 of 41 identified critical products. A bulk drug park in Himachal Pradesh is taking shape.
But the results so far are modest. Domestic API production has expanded, but much of the new output flows into exports rather than displacing Chinese inputs in the domestic market. A base hollowed out over two decades will not be rebuilt by sales-linked incentives alone. India’s R&D spending in pharma is roughly 7 percent of net sales, compared with 15 to 20 percent for global peers.
What the West should do
The argument made by Bhowmick and echoed by other analysts is that India’s API dependency is not India’s problem alone. It is a shared vulnerability of the allied pharmaceutical supply chain. Western governments that rely on Indian generics for their healthcare systems have a direct interest in helping India build alternatives to Chinese inputs.
That could mean co-investment in bulk drug parks, joint qualification of non-Chinese API sources, and shared stockpiling of essential intermediates. It could mean embedding supply chain security provisions in trade agreements. The recently concluded India-EU free trade deal is one channel. It could mean treating India’s self-reliance in strategic pharmaceutical inputs as a contribution to collective resilience, not as a parochial industrial policy.
The alternative is to accept that the pharmacy of the world runs on Chinese chemistry, and that the prescription bottle in an American patient’s hand is only as secure as Beijing’s willingness to keep supplying the ingredients that fill it.